

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Supplementary Material

Summary

Materials and Methods

Fig. S1. Comparison of methods for analysis of point mutations in plasma DNA.

Fig. S2. ctDNA in advanced malignancies, ranking of the fraction of patients with detectable ctDNA.

Fig. S3. Diagram of the assay used to confirm rearrangements in plasma DNA.

Table S1. Summary of tissue mutations, plasma mutations, and clinical information for 410 early- and advanced-stage subjects.

Table S2. Comparison of ctDNA levels assessing point mutations and rearrangements in the same specimens.

Table S3. Comparison between plasma and tumor tissue *KRAS* status in 206 patients with metastatic CRC.

Table S4. Clinical characteristics of patients with discordant tissue and plasma *KRAS* mutation data.

Table S5. Clinical characteristics of patients with false negatives in plasma *KRAS* mutation compared with tissue samples.

Table S6. Association between clinical characteristics and absolute levels of ctDNA.

Table S7. Association between clinical characteristics and ctDNA concentration (log scale) in metastatic CRC patients.

Table S8. Patient characteristics and plasma mutations detected after EGFR blockade.

Resources

File (6-224ra24_r_scripts.zip)

DOWNLOAD

12.68 KB

File (6-224ra24_sm.pdf)

DOWNLOAD

608.76 KB

File (6-224ra24_tables_s1_to_s8.zip)

DOWNLOAD

333.51 KB